BCAX · US market
Bicara Therapeutics Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$1.20bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$185.36m
- Latest-quarter run-rate earnings
- -US$221.74m
- Latest fiscal-year earnings
- -US$137.95m
- Trailing revenue
- US$0.00
- Latest-quarter run-rate revenue
- US$0.00
- Latest fiscal-year revenue
- Unavailable
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- TMED · T. Rowe Price Health Care ETF0.53% weight · Holdings dated 30 June 2026
- ORSIX · North Square Dynamic Small Cap Fund Class I0.26% weight · Holdings dated 31 May 2026
- OPTZ · Optimize Strategy Index ETF0.25% weight · Holdings dated 30 June 2026
- VSFAX · Federated Hermes MDT Small Cap Value Fund Class A0.24% weight · Holdings dated 30 June 2026
- XBI · State Street SPDR S&P Biotech ETF0.24% weight · Holdings dated 21 August 2026
- CMSHX · Columbia Small Cap Growth Fund Class S0.13% weight · Holdings dated 31 May 2026
- PSOAX · JPMorgan Small Cap Value Fund Class A0.11% weight · Holdings dated 30 June 2026
- TNXT · T. Rowe Price Innovation Leaders ETF0.09% weight · Holdings dated 30 June 2026
- JTUAX · JPMorgan U.S. Small Company Fund Class A0.08% weight · Holdings dated 30 June 2026
- FESM · Fidelity Enhanced Small Cap Core ETF0.07% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.